Brief: Sixty Degrees Pharmaceuticals Announces Patent License Agreement To Advance Development Of Tafenoquine
08/04/2025 14:29
April 8 (Reuters) - 60 Degrees Pharmaceuticals Inc SXTP.O: SIXTY DEGREES PHARMACEUTICALS ANNOUNCES PATENT LICENSE AGREEMENT TO ADVANCE DEVELOPMENT OF TAFENOQUINE FOR BABESIOSIS TREATMENT AND PREVENTION WITH YALE SCHOOL OF MEDICINE AND YALE SCHOOL OF PUBLIC HEALTH Source text: ID:nGNX51JxNm Further company coverage: SXTP.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on 60 Degrees Pharmaceuticals
See all newsBrief: 60 Degrees Pharmaceuticals Says May Submit NDA For Tafenoquine To FDA Before End Of Q1 2028 - SEC Filing
U.S. RESEARCH ROUNDUP-Analog Devices, Intuit, NVIDIA
Brief: 60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (Ndin) With FDA For Australian Chestnut Extract
NASDAQ RESUMED AT 10:06 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:55 AM